» Articles » PMID: 8933341

Adverse Psychological Events Occurring in the First Year After Predictive Testing for Huntington's Disease. The Canadian Collaborative Study Predictive Testing

Overview
Journal J Med Genet
Specialty Genetics
Date 1996 Oct 1
PMID 8933341
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A total of 135 participants in the Canadian predictive testing programme for HD were followed for at least one year in one of four study groups: increased risk (n = 37), decreased risk ( n = 58), uninformative (n = 17), or not tested (n = 23). Clinical criteria for an adverse event were a suicide attempt or formulation of a suicide attempt plan, psychiatric hospitalisation, depression lasting longer than two months, a marked increase in substance abuse, and the breakdown of important relationships. Quantitative criteria, as measured by changes on the General Severity Index of the Symptom Checklist 90-R and the Beck Depression Inventory, were also used to identify people who had adverse events. Twenty of the 135 participants (14.8%) had an adverse event. There were no significant differences between those with or without an adverse event with respect to age, sex, marital status, education, psychiatric history, general psychiatric distress, or social supports at baseline. However, evidence for depression was associated with an increased frequency of adverse events (p < 0.04). The adverse events were similar and seen with equivalent frequency in those receiving an increased risk or decreased risk and persons at risk who did not receive a modification of risk. However, a significant difference was found in the timing of adverse events for the increased and decreased risk groups (p < 0.0002). In the increased risk group all of the adverse events occurred within 10 days after results whereas, in the decreased risk group, all of the adverse events occurred six months or later after reviewing test results. These results suggest that people entering into predictive testing with some evidence of clinical depression warrant special vigilance and also suggest that counselling and support should be available for all participants in predictive testing irrespective of the direction of test results.

Citing Articles

Predictive testing for Huntington's disease in a digital age; patient power with potential pitfalls.

Mocanu V, Lindquist S, Hjermind L, Heilmann J, MacLeod R, Lahiri N Eur J Hum Genet. 2025; .

PMID: 39880983 DOI: 10.1038/s41431-025-01793-1.


Predictive Genetic Counseling for Neurodegenerative Diseases: Past, Present, and Future.

Goldman J Cold Spring Harb Perspect Med. 2019; 10(7).

PMID: 31548223 PMC: 7328452. DOI: 10.1101/cshperspect.a036525.


Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure.

Mattos M, Sereika S, Beach S, Kim H, Klunk W, Knox M J Alzheimers Dis. 2019; 71(4):1071-1079.

PMID: 31322563 PMC: 6839594. DOI: 10.3233/JAD-190091.


Improving follow up after predictive testing in Huntington's disease: evaluating a genetic counselling narrative group session.

Stopford C, Ferrer-Duch M, Moldovan R, MacLeod R J Community Genet. 2019; 11(1):47-58.

PMID: 31001731 PMC: 6962407. DOI: 10.1007/s12687-019-00416-9.


Reverse pre-symptomatic testing for Huntington disease: double disclosure when 25% at-risk children reveal the genetic status to their parent.

Bonnard A, Herson A, Gargiulo M, Durr A Eur J Hum Genet. 2018; 27(1):22-27.

PMID: 30206353 PMC: 6303253. DOI: 10.1038/s41431-018-0255-7.


References
1.
Evers-Kiebooms G, Swerts A, Cassiman J, Van Den Berghe H . The motivation of at-risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin Genet. 1989; 35(1):29-40. DOI: 10.1111/j.1399-0004.1989.tb02902.x. View

2.
Kessler S . Psychiatric implications of presymptomatic testing for Huntington's disease. Am J Orthopsychiatry. 1987; 57(2):212-219. DOI: 10.1111/j.1939-0025.1987.tb03531.x. View

3.
Brandt J, Quaid K, Folstein S, Garber P, Maestri N, Abbott M . Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease. JAMA. 1989; 261(21):3108-14. View

4.
Bloch M, Adam S, Wiggins S, Huggins M, Hayden M . Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992; 42(4):499-507. DOI: 10.1002/ajmg.1320420416. View

5.
Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O, Trew M . Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992; 42(4):508-15. DOI: 10.1002/ajmg.1320420417. View